Modern drug discovery relies heavily on predictive analytics, artificial intelligence, and machine learning. As a result, many large pharma and biotech companies are using data science to drive innovation in drug discovery. We speak with Dr. Bülent Kızıltan, Head of Causal & Predictive Analytics • Data Science & AI at the Novartis AI Innovation Center to learn more about the pharmaceutical industry.Read the complete transcript and see other CXOTalk interviews: https://www.cxotalk.com/episode/data-science-predictive-analytics-ai-drug-discovery-novartisSubscribe to our newsletter: https://www.cxotalk.com/subscribe The conversation includes a discussion of these topics:-- AI and data science in pharma-- Talent management and diverse teams in pharma-- Using AI and data science in drug discovery and precision medicine-- Challenges in drug discovery and precision medicine-- How Novartis engages community around AI awareness-- Managing bias in data science and AI-- What are the differences between lab-based and AI-based approaches to drug discovery?-- Advice to business leaders on managing AI teamsDr. Bülent Kızıltan is a scientist and an executive who drives innovation by combining an entrepreneurial mindset with scientific excellence. Currently, he is leading innovation efforts focused on Causal and Predictive Analytics at Novartis. Dr. Kızıltan holds a PhD in astrophysics with a focus on applied mathematics, two MSc degrees in astronomy and astrophysics with a focus on statistics, and graduated summa cum laude as valedictorian with a BSc in physics.